Bright Minds BiosciencesDRUG 
-3.10%24h
Bright Minds Biosciences (DRUG) Stock Overview
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.
DRUG Stock Information
Bright Minds Biosciences (DRUG) Price Chart
Bright Minds Biosciences Overview: Key Details and Summary
Stock data | 2023 | Change |
|---|---|---|
| Price | $1.25 | N/A |
| Market Cap | $4.65M | N/A |
| Shares Outstanding | 3.72M | 50.57% |
| Employees | 0 | N/A |
| Shareholder Equity | 6.60M | -37.41% |
Valuation | 2023 | Change |
|---|---|---|
| P/E Ratio | -0.63 | N/A |
| P/B Ratio | 0.70 | N/A |
Growth | 2023 | Change |
|---|---|---|
| Return on Equity | -0.8207 | N/A |
Earnings | 2023 | Change |
|---|---|---|
| Revenue | $0 | N/A |
| Earnings | -$5.41M | N/A |
| EPS | -1.98 | N/A |
| Earnings Yield | -1.58 | N/A |
Financial Strength | 2023 | Change |
|---|---|---|
| Total Assets | $5.05M | N/A |
| Total Debt | $54.02K | N/A |
| Cash on Hand | $4.96M | N/A |
| Debt to Equity | 0.0313 | -70.94% |
| Cash to Debt | $91.75 | 10.39% |
| Current Ratio | $24.26 | 198.94% |
